基于介孔二氧化硅和聚多巴胺纳米载体递送阿帕替尼的性质研究

Study on the properties of apatinib delivery based on mesoporous silica and polydopamine nanocarriers

目的探讨基于介孔二氧化硅和聚多巴胺的纳米载体递送阿帕替尼的效能。方法利用介孔二氧化硅(MSN)的高效药物递送能力和聚多巴胺(PDA)的pH响应性,采用改进的Stober法制备了介孔二氧化硅纳米粒子,根据静电复合法设计了一种pH响应性聚多巴胺(PDA)包覆的介孔二氧化硅纳米给药系统(MSNs@PDA)。采用扫描电子显微镜(SEM)和Zeta电位改变验证MSNs@PDA系统制备是否成功。测定MSNs@PDA-Apa的载药量和包埋率。CCK-8法评价体外细胞毒性。Transwell法评价细胞迁移。结果扫描电子显微镜(SEM)和Zeta电位改变验证MSNs@PDA-Apa制备成功。MSNs@PDA-Apa的药物载药量为2.4%,包埋率为48%±2.5%。MSNs@PDA-Apa组的细胞毒性呈浓度依赖性,当浓度达到10μg/mL时,PC-9细胞的存活率仅为30%左右。与Apa组相比,MSNs@PDA-Apa组对细胞迁移的效果明显增强。结论MSNs@PDA-Apa具有较高的药物传递效率,表现出对肿瘤细胞的良好杀伤作用,有望为未来的药物传递系统的构筑提供思路和方法。

Objective To explore the efficacy of nanocarriers based on mesoporous silica and polydopamine for delivering apatinib.Methods By utilizing the efficient drug delivery ability of mesoporous silica(MSN)and the pH responsiveness of polydopamine(PDA),mesoporous silica nanoparticles were prepared using an improved Stober method.A pH responsive polydopamine(PDA)coated mesoporous silica nanodrug delivery system was designed based on electrostatic composite method(MSNs@PDA).The success of MSNs@PDA system preparation was verified by scanning electron microscopy(SEM)and Zeta potential changes.The drug loading capacity and embedding rate of MSNs@PDA-Apa were determined.Vitro cytotoxicity was evaluated by the CCK-8 method.Transwell method was used to evaluate cell migration.Results MSNs@PDA system preparation was successful,which was verified by scanning electron microscopy(SEM)and Zeta potential changes.The drug loading capacity of MSNs@PDA-Apa was 2.4%,and the embedding rate was 48%±2.5%.The cytotoxicity of MSNs@PDA-Apa group was concentration dependent,and when the concentration reached 10μg/mL,the survival rate of PC-9 cells was only about 30%.Compared to the Apa group,the effect of MSNs@PDA-Apa group on cell migration was significantly enhanced.Conclusion MSNs@PDA-Apa system preparation has a high drug delivery efficiency and exhibits a good killing effect on tumor cells,which is expected to provide ideas and methods for the construction of future drug delivery systems.